Stem Cells and TIL Therapy: How Two Cancer Patients Responded to a New Immune Cell Treatment

Learn how stem cells and TIL therapy helped two cervical cancer patients achieve tumor control, with clinical case data on safety, immune response, and what it means for future treatment.

When the Body’s Own Immune Cells Become the Treatment

What if the key to fighting cancer was already inside the tumor itself?

That is the central idea behind tumor-infiltrating lymphocyte (TIL) therapy — a form of adoptive cell treatment that collects immune cells naturally found within a patient’s tumor, expands them in a laboratory, and reinfuses them back into the patient in much larger numbers. Closely related to broader stem cell-based immunotherapy strategies, TIL therapy has shown real promise in cancers like advanced melanoma and metastatic breast cancer.

But most of the clinical data so far has come from Western patient populations. For Asian patients — particularly those with advanced cervical cancer — the evidence has been thin. A study published on January 9, 2024, in the International Journal of Women’s Health by a research team from Tianjin Beichen Hospital takes a step toward closing that gap.

Two Patients, One Treatment, Meaningful Results

The study documents two cases of Asian women with advanced cervical cancer who received autologous TIL monotherapy — meaning the treatment used each patient’s own immune cells, with no chemotherapy added alongside it.

Patient 1: 68 Years Old, Stage IV, Exhausted by Chemotherapy

The first patient was a 68-year-old woman diagnosed with stage IV cervical squamous cell carcinoma in November 2021 after presenting with vaginal bleeding. Her diagnosis was confirmed by biopsy and PET-CT imaging.

She went through 10 cycles of chemotherapy between October 2021 and July 2022. Every single cycle left her with severe bone marrow suppression — meaning her immune and blood cell production crashed repeatedly, requiring about a month of recovery each time. It was an exhausting cycle with diminishing returns.

By July 2022, her tumor had grown to 4.5 cm and new metastatic lymph node involvement had appeared near the iliac artery. Her symptoms were worsening. Conventional treatment had clearly reached its limits.

Patient 2: 24 Years Old, Stage IIIB, Progressing Despite Everything

The second patient was a 24-year-old woman diagnosed with stage IIIB cervical adenocarcinoma in November 2022. She had received radiation therapy, chemotherapy, and two rounds of pembrolizumab — an immune checkpoint inhibitor — but her cancer continued to advance rapidly. Her tumor subtype appeared to be poorly responsive to the treatments she received.

Both patients were enrolled in a clinical trial of TIL therapy after meeting the study’s eligibility criteria.

How the Treatment Worked

Before receiving the TIL infusion, both patients underwent lymphodepletion — a preparatory step that temporarily suppresses the existing immune environment to make room for the newly infused cells to expand and function effectively.

Patient 1 received 1 × 10⁹ TIL cells in a 100 mL infusion. Patient 2 received a larger dose of 5.1 × 10⁹ cells in 170 mL. Following infusion, both patients received high-dose interleukin-2 (IL-2) for 10 days — a cytokine that helps the infused T cells survive, multiply, and remain active inside the body.

What Happened Next

Patient 1: Tumor Shrank by 33%

Six weeks after TIL infusion, Patient 1 achieved a partial clinical response. At the 12-week follow-up, her tumor had measurably shrunk — from 4.9 cm at baseline to 3.3 cm at six weeks, and down to 3.0 cm by week 12. That represents a 33% reduction in tumor size. Her vaginal discharge, which had been worsening prior to treatment, disappeared entirely.

The metastatic lymph nodes near her iliac artery remained stable — no further spread. Her tumor biomarkers CA125 and CA153, which are used to track gynaecological cancer activity, both declined after treatment, providing additional evidence that her disease was responding.

Patient 2: Disease Stabilised

Patient 2 achieved stable disease at six weeks. Her tumor measured 5.9 cm before treatment and 5.8 cm at follow-up — effectively unchanged. For a patient whose cancer had been progressing rapidly through multiple prior therapies, halting that progression was a clinically relevant outcome. Her CA125 levels declined modestly, though CA153 did not show a corresponding drop.

Side Effects: Mild and Short-Lived

Both patients experienced side effects following TIL infusion, but all were mild and resolved within seven days without significant medical intervention. This is a notable finding, particularly when compared to the severe bone marrow suppression Patient 1 had endured through each chemotherapy cycle.

What Was Happening Inside the Body

The researchers didn’t just observe what happened on the outside — they tracked the immunological changes occurring within the patients’ bodies throughout treatment.

From around day 17 to 22 after infusion and continuing through week 12, lymphocyte levels in the peripheral blood stayed consistently elevated — between 40% and 70%. This suggests the infused TIL cells were not just surviving but establishing a durable presence in the systemic circulation.

CD8⁺ T cells — the immune system’s primary cancer-killing cells — were found at higher proportions from day 15 onwards. This is consistent with the TIL population expanding and persisting in the bloodstream rather than fading quickly after infusion.

At four to six weeks post-infusion, levels of IFN-γ and TNF-α — two cytokines strongly associated with active antitumour immune activity — rose sharply. The timing of this cytokine surge aligns closely with the tumour regression observed at the six- and 12-week assessments, suggesting a biological connection between immune activation and clinical response.

Elevated neutrophil counts and C-reactive protein (CRP) levels were also noted from day 4 after treatment — indicators of an activated immune response. CRP levels returned to near normal within about a month, suggesting this was a controlled, self-limiting process rather than an ongoing inflammatory complication.

Why This Study Matters

This is a small study — just two patients — and it cannot establish definitive conclusions about TIL therapy’s efficacy on its own. The researchers acknowledge this openly. There is no control group, the two cases have different tumour subtypes and treatment histories, and longer follow-up is needed to understand durability of response.

What it does offer, however, is early clinical evidence that autologous TIL monotherapy can induce meaningful tumour control — and do so safely — in Asian patients with advanced cervical cancer who have already failed or cannot tolerate conventional therapies. In the context of stem cell and cellular immunotherapy research, that is a signal worth paying attention to.

The study also reflects a broader shift in global cellular therapy research: more clinical data is emerging from Asian institutions and being integrated into international scientific discourse. Regulatory agencies including the FDA, EMA, and China’s NMPA are all actively developing frameworks for evaluating adoptive cell therapies, and case-level clinical data like this contributes to the evidence base those frameworks depend on.

The Bottom Line

TIL therapy worked — at least for these two patients. One saw her tumor shrink by a third. The other stopped progressing after running out of conventional options. Both tolerated the treatment far better than chemotherapy. And inside their bodies, the immune system showed clear signs of activation and sustained antitumour engagement.

Larger, controlled trials are needed before TIL therapy can be positioned as a standard option for this patient group. But within the evolving landscape of stem cell-based and adoptive immune cell therapies, this study adds a meaningful piece to a growing picture.